Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20835667 | 1.00 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL31498517 | 0.93 | CTSS (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL28286745 | 0.88 | ITGB3 (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL28286746 | 0.88 | ITGB3 (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL22451614 | 0.87 | CYP1A2 (0.52) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3621626 | 0.85 | HDAC4 (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL22040793 | 0.84 | HDAC4 (0.44) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL22039566 | 0.84 | HDAC4 (0.44) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL31551112 | 0.82 | CTSK (0.58) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3726757 | 0.82 | CTSK (0.58) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| CN-109476639-B | Pyrrolidine derivatives | 橘生药品工业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | CTSK 1544/4885CTSS 1379/4885HDAC4 2760/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | CTSK 1544/4885CTSS 1379/4885HDAC4 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.